Log in

ONO PHARMACEUTI/ADR Stock Price, Forecast & Analysis (OTCMKTS:OPHLY)

$6.67
-0.05 (-0.82 %)
(As of 11/15/2019 08:00 AM ET)
Today's Range
$6.67
Now: $6.67
$6.75
50-Day Range
$5.73
MA: $6.11
$6.72
52-Week Range
$5.60
Now: $6.67
$8.21
Volume54,589 shs
Average Volume19,112 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ono Pharmaceutical Co., Ltd. produces and sells pharmaceuticals and diagnostic reagents worldwide. Its products include OPDIVO intravenous infusions for the treatment of malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; GLACTIV and FORXIGA tablets for type 2 diabetes; KINEDAK tablets to treat diabetic peripheral neuropathy; PARSABIV, an intravenous injection for dialysis patients; RECALBON tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONOACT injections for treating tachyarrhythmia; Staybla tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and Foipan tablets to treat chronic pancreatitis and postoperative reflux esophagitis. The company is also developing products for malignant pleural mesothelioma, glioblastoma, multiple myeloma, solid tumors, chronic myeloid and acute leukemia, melanoma, pheochromocytoma, cancer anorexia/cachexia, ventricular arrhythmia, tachyarrhythmia, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, osteoarthritis, parkinson's disease, enthesopathy, sepsis, hepatitis C, sjögren syndrome, autoimmune disease, and acromegaly; small cell lung, esophageal, gastric or esophago-gastric junction, ovarian, colorectal, pancreatic, prostate, biliary tract, hematologic, small and non-small cell lung, head and neck, and esophageal cancers; hepatocellular, urothelial, virus positive/negative solid, and renal cell carcinoma; and central nervous system, primary testicular, diffuse large B cell, follicular lymphoma, B cell, and non-Hodgkin lymphoma. It has a drug discovery research collaboration with twoXAR, Inc. The company was founded in 1717 and is headquartered in Osaka, Japan.

Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
SectorHealth Technology
Current SymbolOTCMKTS:OPHLY
CUSIPN/A
CIKN/A
Phone(166) 263-5670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees3,480
Next Earnings DateN/A
OptionableNot Optionable

Receive OPHLY News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHLY and its competitors with MarketBeat's FREE daily newsletter.


ONO PHARMACEUTI/ADR (OTCMKTS:OPHLY) Frequently Asked Questions

What is ONO PHARMACEUTI/ADR's stock symbol?

ONO PHARMACEUTI/ADR trades on the OTCMKTS under the ticker symbol "OPHLY."

What is the consensus analysts' recommendation for ONO PHARMACEUTI/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ONO PHARMACEUTI/ADR in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ONO PHARMACEUTI/ADR.

Has ONO PHARMACEUTI/ADR been receiving favorable news coverage?

Media stories about OPHLY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ONO PHARMACEUTI/ADR earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for ONO PHARMACEUTI/ADR.

Who are some of ONO PHARMACEUTI/ADR's key competitors?

What other stocks do shareholders of ONO PHARMACEUTI/ADR own?

Who are ONO PHARMACEUTI/ADR's key executives?

ONO PHARMACEUTI/ADR's management team includes the folowing people:
  • Mr. Gyo Sagara, CEO, Pres & Representative Director
  • Toichi Takino, Corp. Officer, Exec. Director of Discovery & Research
  • Yukio Tani, Corp. Exec. Officer & Director of Corp. Communications
  • Mr. Hiroshi Ichikawa, Corp. Exec. Officer and Exec. Director of Sales & Marketing
  • Mr. Kei Sano, Sr. Exec. Officer & Exec. Director of Gen. Admin. Headquarters and Director

How do I buy shares of ONO PHARMACEUTI/ADR?

Shares of OPHLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ONO PHARMACEUTI/ADR's stock price today?

One share of OPHLY stock can currently be purchased for approximately $6.67.

What is ONO PHARMACEUTI/ADR's official website?

The official website for ONO PHARMACEUTI/ADR is http://www.ono.co.jp/.

How can I contact ONO PHARMACEUTI/ADR?

The company can be reached via phone at (166) 263-5670.


MarketBeat Community Rating for ONO PHARMACEUTI/ADR (OTCMKTS OPHLY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about ONO PHARMACEUTI/ADR and other stocks. Vote "Outperform" if you believe OPHLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel